Gyre Therapeutics (GYRE) Other Non Operating Income (2015 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Other Non Operating Income of $29000.0 for Q1 2026, down 72.9% year-over-year from $107000.0 in Q1 2025, and up 101.32% quarter-over-quarter from -$2.2 million in Q4 2025.
Gyre Therapeutics (GYRE) Other Non Operating Income (2015 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Other Non Operating Income for 12 consecutive years, with $29000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 72.9% year-over-year to $29000.0; the TTM figure through Mar 2026 stood at -$1.6 million (up 5.44% YoY), while the FY2025 annual figure was -$1.5 million, up 9.28% from the prior year.
- Other Non Operating Income grew to $29000.0 in Q1 2026 per GYRE's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $858000.0 in Q4 2022 and bottomed at -$2.2 million in Q4 2025.
- Historically, Other Non Operating Income has averaged -$185470.6 across 5 years, with a median of -$1000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non Operating Income surged 4390.0% — and 2023, when it tumbled 133200.0%.
- Gyre Therapeutics' Other Non Operating Income stood at $858000.0 in 2022, then plunged by 127.62% to -$237000.0 in 2023, then slumped by 589.45% to -$1.6 million in 2024, then slumped by 34.27% to -$2.2 million in 2025, then soared by 101.32% to $29000.0 in 2026.
- Business Quant data shows GYRE's Other Non Operating Income at $29000.0 in Q1 2026, -$2.2 million in Q4 2025, and $727000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -943,000.00 |
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | -2.19 Mn |
| Sep 30, 2025 | 727,000.00 |
| Jun 30, 2025 | -145,000.00 |
| Mar 31, 2025 | 107,000.00 |
| Dec 31, 2024 | -1.63 Mn |
| Sep 30, 2024 | -75,000.00 |
| Jun 30, 2024 | -72,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Dec 31, 2023 | -237,000.00 |
| Sep 30, 2023 | -1.33 Mn |
| Jun 30, 2023 | 629,000.00 |
| Mar 31, 2023 | 66,000.00 |
| Dec 31, 2022 | 858,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | 17,000.00 |
| Mar 31, 2022 | -17,000.00 |
| Dec 31, 2021 | -20,000.00 |
| Sep 30, 2021 | -16,000.00 |